CoChat

Metformin‐induced mitochondrial function and ABCD 2 up‐regulation in X‐linked adrenoleukodystrophy involves AMP‐activated protein kinase

Open access
Singh, Jaspreet, Olle, Brittany, Suhail, Hamid, Felicella, Michelle M., Giri, Shailendra · 2016 · Journal of Neurochemistry
Cited by 24

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

X‐linked adrenoleukodystrophy (X‐ALD) is a progressive neurometabolic disease caused by mutations/deletions in the Abcd1 gene. Similar mutations/deletions in the Abcd1 gene often result in diagonally opposing phenotypes of mild adrenomyeloneuropathy and severe neuroinflammatory cerebral adrenoleukodystrophy (ALD), which suggests involvement of downstream modifier genes. We recently documented the first evidence of loss of AMP‐activated protein kinase α1 (AMPK α1) in ALD patient‐derived cells. Here, we report the novel loss of AMPK α1 in postmortem brain white matter of patients with ALD phenotype. Pharmacological activation of AMPK can rescue the mitochondrial dysfunction and inhibit the pro‐inflammatory response. The FDA approved anti‐diabetic drug Metformin, a well‐known AMPK activator, induces mitochondrial biogenesis and is documented for its anti‐inflammatory role. We observed a dose‐dependent activation of AMPK α1 in metformin‐treated X‐ALD patient‐derived fibroblasts. Metformin also induced mitochondrial oxidative phosphorylation and ATP levels in X‐ALD patient‐derived fibroblasts. Metformin treatment decreased very long chain fatty acid levels and pro‐inflammatory cytokine gene expressions in X‐ALD patient‐derived cells. Abcd2 [adrenoleukodystrophy protein‐related protein] levels were increased in metformin‐treated X‐ALD patient‐derived fibroblasts and Abcd1‐KO mice primary mixed glial cells. Abcd2 induction was AMPK α1‐dependent since metformin failed to induce Abcd2 levels in AMPK α1‐KO mice‐derived primary mixed glial cells. In vivo metformin (100 mg/Kg) in drinking water for 60 days induced Abcd2 levels and mitochondrial oxidative phosphorylation protein levels in the brain and spinal cord of Abcd1‐KO mice. Taken together, these results provide proof‐of‐principle for therapeutic potential of metformin as a useful strategy for correcting the metabolic and inflammatory derangements in X‐ALD by targeting AMPK. imageThere is no effective therapy for inherited peroxisomal disorder X‐linked adrenoleukodystrophy (X‐ALD). We document the therapeutic potential of FDA approved drug, Metformin, for X‐ALD by targeting AMPK. Metformin induced peroxisomal Abcd2 levels in vitro and in vivo. Metformin lowered VLCFA levels, improved mitochondrial function and ameliorated inflammatory gene expression in X‐ALD patient‐derived cells. Metformin‐induced Abcd2 levels were dependent on AMPK α1, a metabolic and anti‐inflammatory gene, recently documented by our laboratory to play a putative role in X‐ALD pathology. Read the Editorial Highlight for this article on page 10.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13562

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 24

Metadata

Authors
Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2016-03-14
Volume
138
Issue
1
Pages
86-100
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2292932642
Cited by
24
References
31
FWCI
2.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin‐induced mitochondrial function and ABCD 2 up‐regulation in X‐linked adrenoleukodystrophy involves AMP‐activated protein kinase. https://app.cochat.ai/papers/10.1111/jnc.13562
The paper
Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S. (2016). Metformin‐induced mitochondrial function and ABCD 2 up‐regulation in X‐linked adrenoleukodystrophy involves AMP‐activated protein kinase. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13562

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.